Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).

Chan, ArleneDelaloge, SuzetteHolmes, Frankie AnnMoy, BeverlyIwata, HirojiHarvey, Vernon J.Robert, Nicholas J.Silovski, TajanaGokmen, ErhanVon Minckwitz, GunterEjlertsen, BentChia, Stephen K. L.Mansi, JanineBarrios, Carlos H.Gnant, MichaelWong, AlvinBryce, RichardYao, BinMartin, Miguel2019-10-272019-10-2720150732-183X1527-7755https://doi.org/10.1200/jco.2015.33.15_suppl.508https://hdl.handle.net/11454/51993Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILen10.1200/jco.2015.33.15_suppl.508info:eu-repo/semantics/closedAccessNeratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).Conference Object3315WOS:000358036901115Q1